The combinational approach of co-targeting a tumor cell antigen (MAGEA4) and a CAF antigen (FAP) may enhance and broaden the anti-tumor immune response, potentially overcoming issues of tumor heterogeneity and antigen loss. The gene discussed is FAP; the disease is neoplasm.